Securities code: Andon Health Co.Ltd(002432) securities abbreviation: Andon Health Co.Ltd(002432) Announcement No.: 2022037 Andon Health Co.Ltd(002432)
Announcement on the progress of major contracts for the daily operation of the company’s U.S. subsidiaries
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and bear joint and several liabilities for false records, misleading statements or major omissions in the announcement. 1、 Contract overview and main contents
Andon Health Co.Ltd(002432) (hereinafter referred to as “the company”) subsidiary ihealth Labs
Representatives of Inc (hereinafter referred to as “U.S. subsidiary”) and ACC (U.S. Army contract management command)
HHS (U.S. Department of health and human services) produces OTC kit for ihealth covid-19 antigen home self-test
Product (hereinafter referred to as “ihealth kit”) signed the purchase agreement on January 13, 2022 local time
The contract (hereinafter referred to as the “contract”) sells 250 million copies of ihealth kit products to it, and the total contract price tax is US $127500000000 (including freight).
On January 26, 2022 US local time, the US subsidiary signed a change contract with ACC on the original purchase contract. Based on the purchase of 250 million ihealth kit products in the original contract, 104166665 ihealth kit products were purchased. Due to the above changes, the total amount of contract price tax increased by 4999999200 US dollars (excluding freight). After this change, the total contract amount increased from USD 127500000000 to USD 1774999200.
For details of the above matters, please refer to the Securities Times published on January 14, 2022 and January 27, 2022
China Securities Journal and cninfo (www.cn. Info. Com. CN.) Announcement on signing major contracts for daily operation of the company’s U.S. subsidiaries (Announcement No.: 2022013) and announcement on progress of major contracts for daily operation of the company’s U.S. subsidiaries (Announcement No.: 2022021). 2、 Contract progress
As of March 10, 2022, the US subsidiary of the company has fulfilled the delivery obligation of the above contract. For details, please refer to the company’s major report on the daily operation of the company’s U.S. subsidiaries disclosed on March 11, 2022
Announcement of contract progress (Announcement No.: 2022026).
On April 14, 2022 local time, ACC of the United States made another payment to the company’s U.S. subsidiary, totaling
The total amount is 410508864 US dollars, about 262298743741 yuan (based on April 15, 2022)
The central parity rate of US dollar to RMB (1 US dollar = 6.3896 yuan).
As of the date of this announcement, ACC of the United States has paid a total of USD 152051435673 to the company’s U.S. subsidiary, about RMB 971547853376 (calculated according to the central rate of USD / RMB exchange rate on April 15, 2022 = RMB 6.3896), and the above funds have arrived in the account. The above conditions are in line with the delivery and payment arrangements stipulated in the contract, which is in the process of normal performance. 3、 Risk tips
The performance of the above contracts will have a positive impact on the company’s operating revenue and operating profit in 2022. During the execution of the contract, there may be risks of failure to perform on schedule or in full. The specific influencing factors are as follows:
1. Quality risk: in the case of mass production, the batches of individual products may have quality problems, leading to the risk of return or even recall. This risk may lead to the buyer’s return, and the seller will bear the relevant losses;
2. Buyer’s risk: up to now, the delivery obligation agreed in the company’s contract has been fulfilled, and payment will be arranged after the buyer’s inspection and receipt. At present, the contract is under normal performance and the buyer has the ability to perform the contract, but there are still risks of the buyer such as delayed payment before all the payment for goods is received;
3. Exchange rate risk: this transaction is settled in US dollars. Exchange rate fluctuations will have an impact on the company’s collection amount denominated in RMB and the amount of recognized operating revenue.
To sum up, the company believes that it is necessary to give sufficient risk tips on the uncertain factors in the performance of the contract. Please pay attention to the investment risks and invest rationally. 4、 Documents for future reference
Relevant certificates of receipt of the company’s U.S. subsidiaries. It is hereby announced
Andon Health Co.Ltd(002432) board of directors April 18, 2022
